United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Boosts Position in Zoetis Inc. (NYSE:ZTS)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 234,860 shares of the company's stock after buying an additional 5,400 shares during the quarter. Zoetis accounts for 1.5% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's investment portfolio, making the stock its 22nd largest position. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund owned approximately 0.05% of Zoetis worth $38,266,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Callahan Advisors LLC boosted its holdings in Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after purchasing an additional 6,221 shares during the period. CIBC Asset Management Inc boosted its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after buying an additional 46,050 shares during the period. Pensionfund Sabic grew its position in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock worth $1,825,000 after buying an additional 4,000 shares in the last quarter. PFW Advisors LLC purchased a new stake in shares of Zoetis during the fourth quarter worth approximately $1,764,000. Finally, Alberta Investment Management Corp raised its holdings in Zoetis by 2,050.0% in the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock valued at $4,904,000 after acquiring an additional 28,700 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research firms have recently issued reports on ZTS. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target on the stock. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $215.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by insiders.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $1.99 on Friday, reaching $163.03. The company's stock had a trading volume of 1,550,283 shares, compared to its average volume of 2,595,079. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The stock has a market capitalization of $73.00 billion, a P/E ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The stock's 50-day moving average is $166.40 and its two-hundred day moving average is $174.55. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis's payout ratio is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.